CFF provided the following clinical trial update on 12/15/2016:

Vertex Lumacaftor (VX-809) and Ivacaftor in Children with CF aged 6 to 11 years and have two copies of the delF508 CFTR mutation

Description: This was an open-label study designed to look at the safety of lumacaftor in combination with ivacaftor (OrkambiĀ®). This study was for younger children with CF who have two copies of the F508del CFTR mutation.

Age: 6 Years to 11 Years

Mutation: Two Copies F508del

Fev1% Predicted: No FEV1 Limit

Number of Visits: 11

Length of Participation: 27 weeks

ClinicalTrials.gov link: https://clinicaltrials.gov/show/NCT01897233